NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRTK shares have increased by 17.2% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals.

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Paratek Pharmaceuticals.

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.66) EPS for the quarter, topping the Zacks' consensus estimate of ($0.80) by $0.14. The specialty pharmaceutical company had revenue of $7.92 million for the quarter, compared to analysts' expectations of $7.75 million. Paratek Pharmaceuticals had a negative net margin of 528.28% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' earnings history.

Paratek Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $81.12 million.

6 brokerages have issued 1-year price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $18.50 in the next year. This suggests a possible upside of 305.7% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals.

Headlines about PRTK stock have trended neutral recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 0.1 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutParatek Pharmaceuticals.

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), EXACT Sciences (EXAS), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.68%), Rock Springs Capital Management LP (3.54%), General American Investors Co. Inc. (1.89%), Granahan Investment Management Inc. MA (1.66%), State Street Corp (1.54%) and Water Island Capital LLC (0.83%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals.

PRTK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Arbiter Partners Capital Management LLC, Water Island Capital LLC, Morgan Stanley, State Street Corp, Parametric Portfolio Associates LLC, and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals.

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Balyasny Asset Management LLC, General American Investors Co. Inc., Nuveen Asset Management LLC, BlackRock Inc., Trellus Management Company LLC, Connor Clark & Lunn Investment Management Ltd., and HighTower Advisors LLC. View insider buying and selling activity for Paratek Pharmaceuticals.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $4.56.

Paratek Pharmaceuticals has a market capitalization of $196.67 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]